Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 231

Results For "NSE"

2554 News Found

Junk food and low physical activity leading to diabetes: ASSOCHAM report
News | November 15, 2021

Junk food and low physical activity leading to diabetes: ASSOCHAM report

Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India


Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22
News | November 13, 2021

Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22

Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021


DawaDost rolls out diabetes medicine at Re 1 per day
Startup | November 13, 2021

DawaDost rolls out diabetes medicine at Re 1 per day

The start-up has announced the scheme to mark World Diabetes Day


Sun Pharma to introduce molnupiravir in India
Drug Approval | November 12, 2021

Sun Pharma to introduce molnupiravir in India

The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India


Covaxin well tolerated with no safety concerns: Lancet
News | November 12, 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%


Clinical study shows ViroStop spray prevents Covid-19
News | November 11, 2021

Clinical study shows ViroStop spray prevents Covid-19

Evidence also shows better immune response to virus among users of spray


Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
News | November 10, 2021

Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years

The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11


US govt places additional order of 1.4 million courses of molnupiravir
News | November 10, 2021

US govt places additional order of 1.4 million courses of molnupiravir

Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults


Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures
Biotech | November 09, 2021

Clarivate and BARDA collaborate to identify therapeutics that can be repurposed for medical countermeasures

Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries


Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively
Biotech | November 09, 2021

Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively

Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma